Literature DB >> 1429973

High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies.

L H Wang1, P C Smith, K L Anderson, R M Fielding.   

Abstract

A sensitive and reproducible high-performance liquid chromatographic method was developed to assay ampherotericin B in plasma, blood, urine and various tissue samples. Amphotericin B was isolated from each sample matrix by solid-phase extraction (Bond-Elut). The eluate from Bond-Elut containing amphotericin B was injected onto a reversed-phase C18 column (Waters, mu Bondpak, 10 microns, 300 mm x 3.9 mm I.D.) with a mobile phase of 45% acetonitrile in 2.5 mM Na2EDTA at 1 ml/min. Detection of amphotericin B was by ultraviolet absorption at 382 nm. Blood and tissues were homogenized and extracted with methanol prior to Bond-Elut extraction. The extraction efficiencies of amphotericin B from plasma, blood and tissues were approximately 90, 70 and 75%, respectively. The sensitivity of the assay was less than or equal to 5 ng/ml for plasma, less than or equal to 25 ng/ml for blood, 2.5 ng/ml for urine and 50 ng/g for tissues. The linearity of the assay method was up to 2.5 micrograms/ml for plasma, 5 micrograms/ml for blood, 500 ng/ml for urine and 500 micrograms/g for tissues. The assay was reproducible with an intra-day coefficient of variation (C.V., n = 3) of less than 5% in general for plasma, blood and tissues. The inter-day C.V. of the assay was less than 5% for plasma (n = 5), less than 10% for blood (n = 4) and less than 5% for tissues (n = 3). The overall variability in the urine assay was generally less than 10%. This method has demonstrated significant improvement in the sensitivity and reproducibility in assaying amphotericin B in plasma and especially in blood, urine and tissues. We have employed this assay to compare the pharmacokinetic and tissue distribution profiles of amphotericin B in rats and dogs following administration of Fungizone and ABCD (amphotericin B-cholesteryl sulfate colloidal dispersion), a lipid-based dosage form. In addition, the assay method for plasma and urine samples can also be applied to pharmacokinetics studies of amphotericin B in man.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1429973     DOI: 10.1016/0378-4347(92)80390-c

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

Authors:  M Paul; R Durand; H Fessi; D Rivollet; R Houin; A Astier; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Pharmacokinetics of liposomal amphotericin B in pleural fluid.

Authors:  Brad Moriyama; Parizad Torabi-Parizi; Alexandra K Pratt; Stacey A Henning; Gennethel Pennick; Yvonne R Shea; Sinchita Roy Chowdhuri; Michael G Rinaldi; A John Barrett; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

4.  Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats.

Authors:  L H Wang; R M Fielding; P C Smith; L S Guo
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.